Emmi D.
- Country
- Finland
- Department
- Medical Oncology
Research Overview
Data & Insights
Has run more than one trial at 0 of 152 partner sites.
Specializations
High‑Risk Neuroblastoma
Focus on pediatric patients diagnosed with high‑risk neuroblastoma requiring intensive multimodal therapy.
- Induction chemotherapy optimization
- High‑dose busulfan/melphalan regimens
- Tandem thiotepa‑based conditioning
Survival outcomes are a central metric of investigation.
High‑Dose Chemotherapy
Application of intensified high‑dose chemotherapy protocols to eradicate residual disease.
- Single Bu‑Mel conditioning
- Tandem thiotepa‑Bu‑Mel sequencing
- Response‑guided dose adjustments
Dose intensity is tailored according to early therapeutic response.
Radiotherapy Strategies
Evaluation of postoperative radiotherapy dose escalation for local disease control.
- Standard 21.6 Gy to tumor bed
- Sequential boost up to 36 Gy for residual disease
- Timing relative to high‑dose chemotherapy
Local control metrics are systematically assessed.
Chemoimmunotherapy
Integration of targeted immunotherapy within chemotherapy regimens, termed chemoimmunotherapy.
- Irinotecan‑temozolomide backbone
- Dinutuximab beta combination
- Metastatic response evaluation per INRC
Approach addresses insufficient responders after induction.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.